Michael Farnsworth, MD
Psychiatry · Mankato, MNNPI 1932183274
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $429,720 of the $547,762 with a category attached, or 78.5%. 8 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 48.4% of the total. Among psychiatry clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 624 payments — averaging $877.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$265K
- Otsuka America Pharmaceutical, Inc.$250K
- E.r. Squibb & Sons, L.L.C.$28K
- Sunovion Pharmaceuticals Inc.$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$114
- plus $133 from 2 others
What the payments were for
- Consulting fees$53,22910%
- Speaking & faculty fees$429,72078%
- Travel & lodging$55,69810%
- Food & beverage$9,0652%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 259 | $265,355 |
| Otsuka America Pharmaceutical, Inc. | 308 | $249,526 |
| E.r. Squibb & Sons, L.L.C. | 33 | $27,830 |
| Sunovion Pharmaceuticals Inc. | 4 | $3,650 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $1,153 |
| Lundbeck LLC | 6 | $114 |
| Alkermes, Inc. | 5 | $88 |
| AbbVie | 2 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$262,010
- ABILIFY MAINTENA$141,169
- REXULTI$103,883
- ABILIFY ASIMTUFII$88,671
- COBENFY$6,054
- LATUDA$3,625
- CAPLYTA$1,000
How this compares
$547,762 in reported general payments places this provider in the 95th percentile of 552 psychiatry providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 11 | $28,293 |
| RexultiBrexpiprazole | 16 | $23,582 |
| Lurasidone Hcl | 30 | $16,835 |
| FetzimaLevomilnacipran Hcl | 15 | $13,353 |
| TrintellixVortioxetine Hydrobromide | 20 | $11,713 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 47 | $6,432 |
| Lisdexamfetamine Dimesylate | 21 | $5,421 |
| Aripiprazole | 36 | $4,139 |
| Bupropion XlBupropion Hcl | 69 | $2,672 |
| Eszopiclone | 16 | $1,777 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $1,760 |
| Fluoxetine Hcl | 13 | $1,712 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 36 | $1,218 |
| Hydroxyzine Hcl | 24 | $1,174 |
| Clonazepam | 78 | $1,051 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,153 | $28,29311 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $249,526 | $23,58216 claims |
| AbbVieFetzima | $45 | $13,35315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 552 psychiatry providers in Minnesota.
Other psychiatry in Mankato
- Danielle Magness-WellmannMankato$232K
- Edward SathoffMankato$1K
- Robert OlsonMankato$1K
- Veronica RadiganMankato$496
- Michael MoellerMankato$483
- Sujit VarmaEdina$581K
- Craig VineSt Paul$136K
- Thomas WinegardenChanhassen$55K
- John LuehrMinnetonka$41K
- Walter RushSaint Paul$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.